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Cystic fibrosis (CF) is a common autosomal recessive disorder with different 
clinical manifestations, mainly in the gastrointestinal and respiratory tracts. 
This study was performed to access the effect of probiotics in the status of 
intestinal inflammation in a group of children with CF by measuring the 
calprotectin level in the fecal samples.
Forty-seven patients with CF were enrolled in this study. The fecal calprotectin 
levels were measured by enzyme linked immunosorbent assay. In a randomized 
systematic method, the children were divided into two groups - one group 
received probiotic powder and another received placebo for four weeks. After 
this period, fecal calprotectin was re-measured.
Thirty-one of 47 enrolled patients (65.9%) had abnormal fecal calprotectin 
levels (>50 g/g). After the intervention, the fecal calprotectin levels decreased 
in 29 patients (21 patients in the drug group, and only 8 patients in the 
placebo group; p<0.001). 
This study showed that about two-thirds of patients with CF had intestinal 
inflammation based on fecal calprotectin levels. Probiotic administration was 
shown to decrease calprotectin concentrations and subsequently intestinal 
inflammation in CF patients.
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Cystic fibrosis (CF) is a common genetic 
disorder occurring in about 1 of 2,500 live 
births in the Caucasian population. CF is 
a chronic debilitating disorder, in which 
pancreatic enzyme replacement therapy cannot 
resolve patients’ gastrointestinal complaints 
completely. High levels of inflammatory markers 
in the blood of CF patients have been reported, 
while their concentrations seem to be correlated 
with the disease severity1-4.
A recent study showed several inflammatory 
findings in patients with CF, such as edema, 
erythema, mucosal breaks, and frank ulcerations 
using capsule endoscopy1. The patients with 
pancreatic insufficiency had higher levels of 
fecal calprotectin, which could also correlate 
with CF findings1. Calprotectin is in a family 
of Ca2+ binding proteins that is basically 
produced by neutrophils, but smaller amounts 
can be found in monocytes and reactive 
macrophages. This molecule is known to be 
bacteriostatic and fungistatic with minimum 
inhibitory concentrations comparable to those 
of antibiotics5,6. 
There are some evidences showing increased 
levels of calprotectin in stool specimens of 
patients with some gastrointestinal disorders, 
including inflammatory bowel diseases (IBDs). 
Recently, calprotectin concentrations have also 
been used to identify the severity of intestinal 
inflammation and the activity of the disease 
in children with IBD5,6. Gray et al.7 found 
serum and sputum calprotectin levels to 
change informatively following treatment of 
CF exacerbations.
This study was performed to assess the 
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effect of probiotics in the status of intestinal 
inflammation in a group of children with CF 
by measuring the calprotectin level in the 
fecal samples.
Material and Methods
Subjects
This study was performed in a group of patients 
with CF, whose diagnosis was made based on 
two positive sweat tests, and who were aged 
over four years. All the patients had steatorrhea 
as a sign of pancreatic insufficiency. They had 
not used any non-steroidal anti-inflammatory 
drug (NSAID) during the last two weeks. The 
patients were not on antibiotic therapy at the 
time of the study. All these patients were 
pediatric cases referred to the gastrointestinal 
clinic of the Children's Medical Center, the 
Pediatrics Center of Excellence in Iran. 
This study was approved by the local Ethics 
Committee of the hospital. Written informed 
consents were obtained from the subjects. This 
study was also registered in the Iranian Registry 
of Clinical Trials (IRCT201201258778N3). 
Although 50 patients were initially selected 
for this study, three patients later decided not 
to participate in this study and did not bring 
the stool samples. Therefore, 47 patients were 
enrolled in the study.
Methods
In a double-blind randomized controlled trial, 
patients were simply randomly divided into two 
groups to receive either probiotic or placebo. 
The probiotic group received one probiotic 
sachet each day for four weeks and the placebo 
group received maltodextrin instead. As a 
double-blind study, neither the patients nor the 
doctors/researchers were aware of the placebo 
or probiotic packs. The probiotic powder used 
in this study was 1 g Protexin Restor sachet, 
which contains of FOS (fructooligosaccharides) 
and a mixture of 1×109 CFU/sachet bacteria 
(Lactobacillus casei, Lactobacillus rhamnosus, 
Streptococcus thermophilus, Bifidobacterium breve, 
Lactobacillus acidophilus, Bifidobacterium infantis 
(child-specific), Lactobacillus bulgaricus). All the 
families were contacted by telephone each 
week to ensure that the patients were using 
the packs regularly.
Calprotectin
A stool specimen was collected from the 
patients at the beginning of the study. After 
four weeks, another fecal sample was taken 
from the patients. The samples were stored 
at -80°C in the laboratory of the hospital 
until the time of assay. Once fecal calprotectin 
concentrations were measured, 0.1 g frozen 
feces were suspended in extraction buffer, 
homogenized and centrifuged. The supernatant 
was collected and assayed using enzyme linked 
immunosorbent assay (ELISA kit, Hycult 
Biotech, Uden, Netherlands) with a specific 
polyclonal antibody. The upper normal limit 
for fecal calprotectin is 50 µg/g.
Statistics
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS) 
software, version 16.0. For the qualitative 
variables, descriptive methods were used and 
the frequencies of variables were presented, 
while for quantitative variables, the results were 
expressed as mean±SD (standard deviation). 
In order to analyze the changes in fecal 
calprotectin levels before and after probiotic 
administration, t test was used.
Results
Forty-seven children with CF were enrolled 
in this study and divided into two groups, as 
probiotic (n=24), with mean age of 8.56±4.19 
years, or placebo (n=23), with mean age of 
8.65±3.29 years. 
Before intervention After intervention
Groups Fecal calprotectin >50 µg/g
Fecal calprotectin 
<50 µg/g
Fecal calprotectin 
>50 µg/g
Fecal calprotectin 
<50 µg/g
Placebo 13 10 8 15
Probiotic 18 6 21 3
Total 31 16 29 18
Table I. Fecal Calprotectin Concentrations in Patients with CF Before and After Intervention
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Mean fecal calprotectin concentrations in the 
probiotic and placebo groups before intervention 
were 101.38 µg/g and 70.22 µg/g, respectively, 
and there was no significant difference between 
the two groups (p=0.1). However, the mean 
fecal calprotectin concentration after using 
probiotic powders was 56.2 µg/g, which was 
significantly lower than 182.1 µg/g in the 
placebo group (p=0.031).
Among the 47 CF patients, 31 patients (65.9%) 
had fecal calprotectin levels of more than 50 
g/g. Although 13 patients (41.9%) belonged to 
the placebo and 18 patients (58.1%) belonged 
to the probiotic group in random allocation 
(Table Ι), this difference was not significant 
(p=0.230). However, after intervention, 29 
patients had fecal calprotectin concentrations 
less than 50 µg/g; among them, 8 patients 
(27.6%) were in the placebo and 21 patients 
(72.4%) were in the probiotic group. There 
was a significantly lower number of cases with 
high calprotectin level in the patients who used 
probiotic (p<0.001).
Discussion
Fecal calprotectin concentrations have been 
used as a non-invasive valid marker for 
intestinal inflammation3,5. In this study, we 
used this marker to evaluate the effect of a 
probiotic in a group of patients with CF.
Fagerberg et al.3 showed that the mean fecal 
calprotectin levels in children with colorectal 
inflammation were greater than the ones 
without colorectal inflammation. The level of 
50 µg/g is considered as the upper normal 
limit for fecal calprotectin concentration, with 
95% sensitivity and 93% specificity. At the 
beginning of our study, we found that about 
two-thirds of the patients with CF had fecal 
calprotectin concentrations of more than 50 
µg/g. Bruzzese et al.8 also reported that fecal 
calprotectin levels were significantly higher in 
children with CF compared to healthy controls. 
It seems that there is a compromised intestinal 
barrier function in CF patients, while there 
are increased concentrations of inflammatory 
substances in the whole gut lavage of CF 
patients1. 
There are some controversies on the initial event 
causing inflammatory states in CF patients; 
some groups believe that bacterial infections 
initiate the inflammatory responses, while others 
believe that dysregulation in inflammatory 
processes and cellular defects can predispose 
them to infections2,9. In support of this link 
between intestinal bacterial overgrowth and 
inflammation, the expression of inflammatory-
related genes decreased when treating CF 
mice with proven intestinal dysbiosis with 
antibiotics10. One theory about the persistent 
abdominal complaints in CF patients is the 
presence of abdominal inflammation, which 
could be due in part to microflora changes. 
Therefore, if probiotic administrations in CF 
patients palliate the intestinal symptoms and 
reduce the fecal calprotectin concentrations, it 
could support this hypothesis. 
Probiotic bacteria seem to be beneficial in 
treating some intestinal disorders, including 
acute gastroenteritis and IBD8. In our study, 
probiotic administration significantly changed 
the fecal calprotectin concentrations compared 
to the placebo group, so the microflora 
modifications can improve the intestinal 
inflammation. The result of this study was in 
agreement with a previous study by Bruzzese 
et al.8, which showed that the calprotectin 
level is lessened after probiotic administration. 
In a study by Lisowska et al.9, they found 
significantly higher fecal calprotectin levels 
in CF patients in comparison with controls, 
but calprotectin levels did not differ between 
small bowel bacterial overgrowth-positive and 
-negative patients. Thus, fecal calprotectin level 
may not be a sufficient marker of intestinal 
inflammatory status. It should be noted that 
since the number of cases included in this 
study was limited, further studies are needed 
to check different inflammatory markers in 
patients with CF, while the efficacy of probiotics 
should be checked over longer time periods.
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